EA201791222A1 - Противораковые композиции - Google Patents

Противораковые композиции

Info

Publication number
EA201791222A1
EA201791222A1 EA201791222A EA201791222A EA201791222A1 EA 201791222 A1 EA201791222 A1 EA 201791222A1 EA 201791222 A EA201791222 A EA 201791222A EA 201791222 A EA201791222 A EA 201791222A EA 201791222 A1 EA201791222 A1 EA 201791222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arn
prostate cancer
hpmcas
resistant prostate
solid dispersion
Prior art date
Application number
EA201791222A
Other languages
English (en)
Inventor
Деннис Мартин Хестер
Джейсон Майкл Вон
Original Assignee
Арагон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арагон Фармасьютикалз, Инк. filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA201791222A1 publication Critical patent/EA201791222A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим составам ARN-509, которые можно вводить млекопитающему, в частности человеку, страдающему заболеванием или состоянием, связанным с андрогеновым рецептором (AR), в частности раком, в особенности раком предстательной железы, включая, без ограничений, кастрационно-резистентный рак предстательной железы, метастатический кастрационно-резистентный рак предстательной железы, ранее не подвергавшийся химиотерапии метастатический кастрационно-резистентный рак предстательной железы, биохимически рецидивирующий гормоночувствительный рак предстательной железы или характеризующийся высоким риском неметастатический кастрационно-резистентный рак предстательной железы. В одном аспекте эти составы содержат твердую дисперсию ARN-509 и HPMCAS. В одном аспекте твердую дисперсию ARN-509 и HPMCAS можно получить, в частности ее получают посредством экструзии расплава смеси, содержащей ARN-509 и HPMCAS, и необязательно последующего помола указанной экструдированной из расплава смеси. В одном аспекте твердую дисперсию ARN-509 и HPMCAS можно получить, в частности ее получают посредством распылительной сушки смеси, содержащей ARN-509 и HPMCAS в приемлемом растворителе.
EA201791222A 2014-12-05 2015-12-03 Противораковые композиции EA201791222A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
EA201791222A1 true EA201791222A1 (ru) 2017-09-29

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791222A EA201791222A1 (ru) 2014-12-05 2015-12-03 Противораковые композиции

Country Status (22)

Country Link
US (2) US20170360754A1 (ru)
EP (1) EP3226841A1 (ru)
JP (2) JP6937692B2 (ru)
KR (2) KR20200141533A (ru)
CN (2) CN106999431B (ru)
AR (1) AR102926A1 (ru)
AU (3) AU2015358490B2 (ru)
BR (1) BR112017011788A2 (ru)
CA (1) CA2969656A1 (ru)
CL (1) CL2017001371A1 (ru)
CO (1) CO2017005572A2 (ru)
CR (1) CR20170216A (ru)
EA (1) EA201791222A1 (ru)
IL (2) IL252323B (ru)
MA (1) MA41107A (ru)
MX (2) MX2017007203A (ru)
NZ (2) NZ731963A (ru)
PH (1) PH12017500964A1 (ru)
SG (1) SG11201704267VA (ru)
TW (2) TWI702966B (ru)
UA (1) UA120950C2 (ru)
WO (1) WO2016090098A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
EP3918607A1 (en) 2019-01-30 2021-12-08 Janssen Pharmaceutica NV Methods of treating prostate cancer based on molecular subtypes
AU2020215176A1 (en) 2019-01-30 2021-08-05 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
CA3160121A1 (en) 2019-11-04 2021-05-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202228794A (zh) 2020-09-04 2022-08-01 美商艾瑞岡醫藥公司 用於治療前列腺癌之方法
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
MXPA03011933A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
TWI532732B (zh) 2012-06-07 2016-05-11 亞拉岡製藥公司 雄性激素受體調節劑之晶型
WO2014031422A1 (en) * 2012-08-24 2014-02-27 Dow Global Technologies Llc Novel hydroxyalkyl methyl cellulose acetate succinates
CN109897004A (zh) * 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EA030128B1 (ru) * 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
BR112016002970A2 (pt) * 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
EA201891397A1 (ru) * 2014-02-05 2019-03-29 Лек Фармасьютикалз Д.Д. Твердые фармацевтические композиции антагонистов рецепторов андрогенов
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses

Also Published As

Publication number Publication date
PH12017500964A1 (en) 2017-10-18
NZ731963A (en) 2024-03-22
SG11201704267VA (en) 2017-06-29
IL252323A0 (en) 2017-07-31
KR20170086656A (ko) 2017-07-26
KR20200141533A (ko) 2020-12-18
AU2021201979B2 (en) 2023-02-02
TWI754258B (zh) 2022-02-01
AU2023202710A1 (en) 2023-05-18
US20170360754A1 (en) 2017-12-21
AU2015358490A1 (en) 2017-06-08
MX2017007203A (es) 2017-08-28
BR112017011788A2 (pt) 2017-12-26
CL2017001371A1 (es) 2018-01-05
TW201630592A (zh) 2016-09-01
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
TWI702966B (zh) 2020-09-01
AR102926A1 (es) 2017-04-05
TW202031248A (zh) 2020-09-01
KR102348320B1 (ko) 2022-01-10
US20230233529A1 (en) 2023-07-27
CR20170216A (es) 2017-08-30
MA41107A (fr) 2017-10-10
IL279833B (en) 2022-03-01
CN114886852A (zh) 2022-08-12
UA120950C2 (uk) 2020-03-10
CO2017005572A2 (es) 2017-09-20
JP2020143069A (ja) 2020-09-10
CN106999431A (zh) 2017-08-01
JP6937692B2 (ja) 2021-09-22
CA2969656A1 (en) 2016-06-09
IL252323B (en) 2021-04-29
JP2017536398A (ja) 2017-12-07
AU2015358490B2 (en) 2021-04-08
CN106999431B (zh) 2022-03-04
EP3226841A1 (en) 2017-10-11
IL279833A (en) 2021-01-31
JP7174006B2 (ja) 2022-11-17
MX2021013965A (es) 2022-01-04
AU2021201979A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
EA201791222A1 (ru) Противораковые композиции
CY1124504T1 (el) Αντικαρκινικες συνθεσεις
EA201791252A1 (ru) Противораковые композиции
MX2020012562A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
EA201891397A1 (ru) Твердые фармацевтические композиции антагонистов рецепторов андрогенов
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EA201792520A2 (ru) Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
MX2017014375A (es) Moduladores del ccr2.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
HK1253277A1 (zh) Ep4受體拮抗劑用於治療nash相關肝癌的用途
CL2016002839A1 (es) Derivados de carboxamida
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
EA201892828A1 (ru) Противораковые композиции
CY1119907T1 (el) Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου
EA201992835A1 (ru) Противораковая комбинированная терапия